## Amendments to the Claims:

This listing of the claims will replace all prior versions, and listings, of claims in the application.

- 1. (Withdrawn) A method for treating ischemic heart diseases, which comprises the step of administering angiopoietin-1 or a vector encoding angiopoietin-1.
- 2. (Withdrawn) The method for treating ischemic heart diseases according to claim 1, which comprises the step of administering angiopoietin-1 or a vector encoding angiopoietin-1, and in which a vascular endothelial growth factor is not administered.
- 3. (Withdrawn) The method according to claim 1 or 2, wherein the vector encoding angiopoietin-1 is a viral vector.
- 4. (Withdrawn) The method according to claim 3, wherein the viral vector is an adenoviral vector.
- 5. (Withdrawn) The method according to claim 3, wherein the viral vector is a minus-strand RNA viral vector.

- 6. (Withdrawn) The method according to claim 1 or 2, wherein the vector encoding angiopoietin-1 is a naked DNA.
- 7. (Withdrawn) The method according to any one of claims 1 to 6, wherein the vector encoding angiopoietin-1 is a vector that drives angiopoietin-1 expression using a CA promoter or a promoter having a transcriptional activity equivalent to or higher than that of said CA promoter.
- 8. (Withdrawn) The method according to any one of claims 1 to 7, wherein the administration of angiopoietin-1 or the vector encoding angiopoietin-1 is an injection into cardiac muscle.
- 9. (Withdrawn) A method for treating ischemic diseases, which comprises the step of administering a viral vector encoding angiopoietin-1.
- 10. (Withdrawn) The method for treating ischemic diseases according to claim 9, which comprises the step of administering a viral vector encoding angiopoietin-1, and wherein a vascular endothelial growth factor is not administered.
  - 11. (Withdrawn) The method according to claim 9 or 10, wherein the viral vector

is an adenoviral vector.

- 12. (Withdrawn) The method according to claim 9 or 10, wherein the viral vector is a minus-strand RNA viral vector.
- 13. (Withdrawn) The method according to any one of claims 9 to 12, wherein the vector administration is an injection into an ischemic site.
  - 14. (Cancelled)
- 15. (Withdrawn) The mesenchymal cell according to claim 14, into which an adenoviral vector encoding angiopoietin-1 has been introduced.
- 16. (Currently Amended) The An isolated mesenchymal cell according to claim

  14, into which comprising a minus-strand RNA viral vector encoding angiopoietin-1 has been introduced.
- 17. (Currently Amended) A therapeutic composition for ischemia, which comprises the mesenchymal cell according to any one of claims 14 to claim 16 and a pharmaceutically acceptable carrier.

- 18. (Withdrawn) A method for producing a genetically modified mesenchymal cell, wherein the method comprises the step of contacting the mesenchymal cell with a minus-strand RNA viral vector carrying a gene.
- 19. (Withdrawn) The method according to claim 18, wherein the gene encodes angiopoietin-1.
- 20. (Previously Presented) The mesenchymal cell according to claim 16, wherein the minus-strand RNA viral vector is a Sendai viral vector.
- 21. (Previously Presented) A therapeutic composition for ischemia, which comprises the mesenchymal cell according to claim 20.
- 22. (New) The mesenchymal cell according to claim 16, wherein the cell is a mesenchymal stem cell.
- 23. (New) The mesenchymal cell according to claim 20, wherein the cell is a mesenchymal stem cell.
  - 24. (New) The therapeutic composition according to claim 17, wherein the cell is

a mesenchymal stem cell.

25. (New) The therapeutic composition according to claim 21, wherein the cell is a mesenchymal stem cell.